{
  "actions": [
    {
      "acted_at": "2006-04-06",
      "action_code": "Intro-H",
      "references": [],
      "text": "Introduced in House",
      "type": "action"
    },
    {
      "acted_at": "2006-04-06",
      "action_code": "H11100",
      "committees": [
        "HSWM"
      ],
      "references": [],
      "status": "REFERRED",
      "text": "Referred to the House Committee on Ways and Means.",
      "type": "referral"
    }
  ],
  "amendments": [],
  "bill_id": "hr5115-109",
  "bill_type": "hr",
  "by_request": false,
  "committee_reports": [],
  "committees": [
    {
      "activity": [
        "referral"
      ],
      "committee": "House Ways and Means",
      "committee_id": "HSWM"
    }
  ],
  "congress": "109",
  "cosponsors": [
    {
      "bioguide_id": "E000187",
      "district": "3",
      "name": "English, Phil",
      "original_cosponsor": true,
      "sponsored_at": "2006-04-06",
      "state": "PA",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "R000033",
      "district": "3",
      "name": "Ramstad, Jim",
      "original_cosponsor": false,
      "sponsored_at": "2006-04-27",
      "state": "MN",
      "title": "Rep.",
      "withdrawn_at": null
    },
    {
      "bioguide_id": "W000273",
      "district": "11",
      "name": "Weller, Jerry",
      "original_cosponsor": true,
      "sponsored_at": "2006-04-06",
      "state": "IL",
      "title": "Rep.",
      "withdrawn_at": null
    }
  ],
  "enacted_as": null,
  "history": {
    "active": false,
    "awaiting_signature": false,
    "enacted": false,
    "vetoed": false
  },
  "introduced_at": "2006-04-06",
  "number": "5115",
  "official_title": "To amend the Internal Revenue Code of 1986 to modernize the tax treatment of biomedical research corporations.",
  "popular_title": null,
  "related_bills": [],
  "short_title": "U.S. Healthcare Technologies Competitiveness Act of 2006",
  "sponsor": {
    "bioguide_id": "H001033",
    "district": "4",
    "name": "Hart, Melissa A.",
    "state": "PA",
    "title": "Rep.",
    "type": "person"
  },
  "status": "REFERRED",
  "status_at": "2006-04-06",
  "subjects": [
    "Accounting",
    "Biomedical engineering",
    "Biotechnology",
    "Capital gains tax",
    "Charities",
    "Clinical trials",
    "Commerce",
    "Corporate finance",
    "Corporation taxes",
    "Depreciation and amortization",
    "Drug industry",
    "Drugs",
    "Finance and Financial Sector",
    "Foundations",
    "Government Operations and Politics",
    "Government paperwork",
    "Health",
    "Hospitals",
    "Income tax",
    "Influenza",
    "Interest",
    "Investments",
    "Losses",
    "Medical innovations",
    "Medical research",
    "Medical supplies",
    "Minimum tax",
    "Orphan drugs",
    "Pharmaceutical research",
    "Real estate development",
    "Research and development tax credit",
    "Research centers",
    "Science, Technology, Communications",
    "Scientific instruments and apparatus",
    "Small business",
    "Social Welfare",
    "Stocks",
    "Tax credits",
    "Tax deductions",
    "Tax exclusion",
    "Tax incentives",
    "Tax-exempt securities",
    "Taxation",
    "Technology transfer",
    "Vaccines",
    "Valuation"
  ],
  "subjects_top_term": "Taxation",
  "summary": {
    "as": "Introduced in House",
    "asOf": "2006-04-06",
    "date": "2006-05-13T14:15:30Z",
    "text": "U.S. Healthcare Technologies Competitiveness Act of 2006 - Amends the Internal Revenue Code to provide tax incentives for investment in biomedical research corporations and related entities, by: (1) exempting investors in biomedical research corporations from limitations on net operating losses acquired through stock sales and mergers involving such corporations; (2) permitting a complete offset against the alternative minimum tax for the net operating losses of biomedical research corporations; (3) making permanent and increasing the rates for the tax credit for increasing research activities; (4) allowing tax credits for countermeasures equity investments and research expenses, qualified medical innovation expenses, equity investments in incubational companies, and investment in qualified biotechnology zone bonds; (5) accelerating eligibility for the tax credit for orphan drug expenses; (6) allowing expensing of biotechnology science park property and medical research equipment; (7) allowing deferral of the tax on gain from the sale of stock in a biomedical research corporation; (8) increasing the tax deductibility of capital losses on the sale of stock in biomedical research corporations; and (9) modifying passive loss deduction rules and S corporation shareholder requirements for biomedical research corporations."
  },
  "titles": [
    {
      "as": null,
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "U.S. Healthcare Technologies Competitiveness Act of 2006",
      "type": "display"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "To amend the Internal Revenue Code of 1986 to modernize the tax treatment of biomedical research corporations.",
      "type": "official"
    },
    {
      "as": "introduced",
      "is_for_portion": false,
      "textVersionCode": null,
      "title": "U.S. Healthcare Technologies Competitiveness Act of 2006",
      "type": "short"
    }
  ],
  "updated_at": "2023-01-13T04:48:45Z",
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/109/hr/BILLSTATUS-109hr5115.xml"
}